192 related articles for article (PubMed ID: 33386905)
21. Hypoxia-induced modulation of glucose transporter expression impacts
Xia H; Chen J; Gao H; Kong SN; Deivasigamani A; Shi M; Xie T; Hui KM
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):787-797. PubMed ID: 31832727
[TBL] [Abstract][Full Text] [Related]
22. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
[TBL] [Abstract][Full Text] [Related]
23. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma.
Lee SD; Kim SH; Kim YK; Kim C; Kim SK; Han SS; Park SJ
Transpl Int; 2013 Jan; 26(1):50-60. PubMed ID: 23106431
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of pre-and postoperative 18F-FDG PET/CT in patients undergoing liver transplantation for hepatocellular carcinoma.
Wang XL; Li H; Wang QS; Zhang XL
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1087-91, 1095. PubMed ID: 16939890
[TBL] [Abstract][Full Text] [Related]
25. Impact of metabolic indices of
Bauschke A; Altendorf-Hofmann A; Brückner L; Drescher R; Freesmeyer M; Settmacher U
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1401-1410. PubMed ID: 35451699
[TBL] [Abstract][Full Text] [Related]
26. Tumor-to-muscle ratio of 8F-FDG PET for predicting histologic features and recurrence of HCC.
Baek YH; Lee SW; Jeong YJ; Jeong JS; Roh YH; Han SY
Hepatogastroenterology; 2015; 62(138):383-8. PubMed ID: 25916068
[TBL] [Abstract][Full Text] [Related]
27.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
28. Does dual-time-point
Wu B; Zhao Y; Zhang Y; Tan H; Shi H
Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of
Grut H; Dueland S; Line PD; Revheim ME
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):218-225. PubMed ID: 29026950
[TBL] [Abstract][Full Text] [Related]
30. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
[TBL] [Abstract][Full Text] [Related]
31. The value of preoperative 18F-FDG PET metabolic and volumetric parameters in predicting microvascular invasion and postoperative recurrence of hepatocellular carcinoma.
Jiang C; Ma G; Liu Q; Song S
Nucl Med Commun; 2022 Jan; 43(1):100-107. PubMed ID: 34456318
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients.
Kornberg A; Freesmeyer M; Bärthel E; Jandt K; Katenkamp K; Steenbeck J; Sappler A; Habrecht O; Gottschild D; Settmacher U
Am J Transplant; 2009 Mar; 9(3):592-600. PubMed ID: 19191771
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic test accuracies of F-18 FDG PET/CT for prediction of microvascular invasion of hepatocellular carcinoma: A meta-analysis.
Kim K; Kim SJ
Clin Imaging; 2021 Nov; 79():251-258. PubMed ID: 34157501
[TBL] [Abstract][Full Text] [Related]
34. Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study.
Shin DY; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
Cancer Chemother Pharmacol; 2011 Jul; 68(1):165-75. PubMed ID: 20872146
[TBL] [Abstract][Full Text] [Related]
35. SUV max as Predictor of Metastatic Disease on 18 F-FDG PET-CT in Hepatocellular Carcinoma.
Ashfaq W; Rehman K; Shahid A; Younis MN
J Coll Physicians Surg Pak; 2024 Apr; 34(4):394-399. PubMed ID: 38576279
[TBL] [Abstract][Full Text] [Related]
36. Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.
Zhou X; Hu Y; Sun H; Chen R; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3107-3115. PubMed ID: 37147479
[TBL] [Abstract][Full Text] [Related]
37. FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study.
Ling LL; Hsu CC; Yong CC; Elsarawy AM; Chan YC; Wang CC; Li WF; Lin TL; Kuo FY; Cheng YF; Lin LM; Chen CL; Lin CC
Int J Surg; 2019 Sep; 69():124-131. PubMed ID: 31386913
[TBL] [Abstract][Full Text] [Related]
38. An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation.
Miao W; Nie P; Yang G; Wang Y; Yan L; Zhao Y; Yu T; Yu M; Wu F; Rao W; Wang Z
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3656-3665. PubMed ID: 33813592
[TBL] [Abstract][Full Text] [Related]
39. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation.
Kornberg A; Küpper B; Tannapfel A; Büchler P; Krause B; Witt U; Gottschild D; Friess H
Liver Transpl; 2012 Jan; 18(1):53-61. PubMed ID: 21850692
[TBL] [Abstract][Full Text] [Related]
40. Exploring the efficacy of
Yin Y; Liu J; Sun R; Liu X; Zhou Z; Zhang H; Li D
Abdom Radiol (NY); 2023 Nov; 48(11):3408-3419. PubMed ID: 37682282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
